Posted by Michael Wonder on 07 Nov 2022
PHARMAC widens access to pneumococcal vaccine
7 November 2022 - PHARMAC has announced today that all young tamariki will receive access to the PCV13 pneumococcal vaccine (Prevenar 13) as part of the childhood immunisation programme, instead of the currently funded PCV10 vaccine (Synflorix).
PCV13 vaccine is currently only funded for high-risk individuals.
